JPMorgan analyst Anupam Rama downgraded iTeos Therapeutics (ITOS) to Neutral from Overweight.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics Ends Collaboration with GSK
- GSK, iTeos ending development program for belrestotug
- iTeos Therapeutics, GSK agree to terminate belrestotug development program
- iTeos Therapeutics initiates targeted review of strategic alternatives
- iTeos: GALAXIES Lung-201 did not meet criteria for meaninful improvements in PFS